Rani Therapeutics (RANI)
(Delayed Data from NSDQ)
$2.30 USD
-0.10 (-4.17%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $2.31 +0.01 (0.43%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Rani Therapeutics Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 3 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 3 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 66 | 63 | 54 | 17 | 0 |
Income After Depreciation & Amortization | -66 | -63 | -52 | -17 | 0 |
Non-Operating Income | 3 | 1 | -1 | 0 | NA |
Interest Expense | 5 | 1 | 0 | 0 | NA |
Pretax Income | -68 | -63 | -53 | -17 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | -34 | -33 | -45 | -17 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -68 | -63 | -53 | -17 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -34 | -31 | -8 | 0 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -67 | -64 | -51 | -16 | 0 |
Depreciation & Amortization (Cash Flow) | -1 | 0 | 1 | 1 | NA |
Income After Depreciation & Amortization | -66 | -63 | -52 | -17 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 25.51 | 23.82 | 19.53 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.33 | -1.28 | -0.43 | NA | NA |
Diluted Net EPS (GAAP) | -1.33 | -1.28 | -0.43 | NA | NA |
Fiscal Year end for Rani Therapeutics Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 12.53 | 14.04 | 13.44 | 17.86 | 18.30 |
Income After SG&A, R&D, and Dept/Amort Expenses | -12.53 | -14.04 | -13.44 | -17.86 | -18.30 |
Non-Operating Income | 0.44 | 0.55 | 0.68 | 0.84 | 0.90 |
Interest Expense | 1.28 | 1.29 | 1.30 | 1.32 | 1.27 |
Pretax Income | -13.36 | -14.78 | -14.06 | -18.33 | -18.66 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | -6.56 | -7.30 | -6.96 | -9.14 | -9.36 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -13.36 | -14.78 | -14.06 | -18.33 | -18.66 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -6.81 | -7.48 | -7.10 | -9.20 | -9.30 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 26.32 | 26.03 | 25.87 | 25.55 | 25.35 |
Diluted EPS Before Non-Recurring Items | -0.26 | -0.29 | -0.27 | -0.36 | -0.37 |
Diluted Net EPS (GAAP) | -0.26 | -0.29 | -0.27 | -0.36 | -0.37 |